Onko Pharmaceuticals has first taken its place in pharmaceutical sector in 1987 by introducing blood derivative products in Turkey, and by getting distribution on exclusive base from the best known pharmaceutical companies of Europe. Until now Onko keeps on serving in this field by still being the leading importer of blood products through satisfying the high need of blood products in Turkey on a large scale.
In 1995, Kocsel Pharmaceuticals has joined to the family with hepatitis B vaccine and biological product group. In subsequent years, it has undertaken the mission of providing a part of Turkeys vaccine needs, which has occurred due to the attendance of Turkey to the global immunization program. After one year, as a result of success in its own sector; Onko & Kocsel Pharmaceuticals, has achieved to extend its horizon in the pharmaceutical sector by setting up an oncology business unit.
In 2002, Onko & Kocsel Pharmaceuticals took the first step on manufacturing by taking over manufacturing licenses from Roche Pharmaceuticals. This brought a new vision to Onko & Kocsel Pharmaceuticals.
Onko & Kocsel Pharmaceuticals has achieved to reflect its fast success also to its organizational structure and adapted Total Quality System to mantain professional management.
Onko & Kocsel Pharmaceuticals focused on adding new products to its mainly Oncology, Radiation Oncology, Hematology, Neurology, Infection diseases, Urology, Physical Medicine & Rehabilitation, Orthopedics, Rheumatology, Immunology, Dermatology and Internal Medicine portfolio year after year. With its dedicated staff and well organized and positioned structure Onko & Kocsel Pharmaceuticals has reached its target consumers throughout Turkey. In the medical marketing; strong professional customer-focused relations, effective meeting organizations, effective communication skills, power of investment and clinically-focused scientific approaches have constituted its vision. Onko & Kocsel Pharmaceuticals plays a significant role with well-educated, professionally trained, experienced, dynamic and result oriented sale force.
Onko & Kocsel keeps showing promising rise by signing new business agreements with strong companies and expanding its product portfolio in the light of innovative and stable development. Onko & Kocsel Pharmaceuticals looks ahead with confidence with an experience more than 20 years in the Pharmaceutical market.
Contact Details
Onko ilaç San. ve Tic. A.Ş.
| Koşuyolu Cad. No:34 34718 Koşuyolu Kadıköy – İstanbul / Türkiye | ||
| Tel: +90 216 544 90 00 | ||
| Fax: +90 216 545 59 94 | ||
| Email: info@onkokocsel.com |
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s…
A roundup of the latest pharma and healthcare news from Turkey including Roche Turkey’s digital platform for HCPs and patients, big pharma’s aid to earthquake victims, the Scientific and Technological…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for…
Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in…
As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…
Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items…
See our Cookie Privacy Policy Here
